Related Experiment Video
Updated: Feb 3, 2026

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
Published on: February 24, 2014
Probiotics and carriage of Streptococcus pneumoniae serotypes in Danish children, a double-blind randomized
Sine Fjeldhøj1, Rikke Pilmann Laursen2, Anni Larnkjær2
1Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, 2300, Denmark.
Insights
Probiotics did not affect Streptococcus pneumoniae carriage in Danish children. Carriage rates increased significantly, with children carrying serotypes not typically causing invasive pneumococcal disease (IPD) in the elderly.
Area of Science:
- Microbiology
- Pediatrics
- Immunology
Background:
- Streptococcus pneumoniae carriage is common in young children.
- Understanding carriage dynamics is crucial for preventing invasive pneumococcal disease (IPD).
- Probiotics are explored for their potential impact on respiratory pathogens.
Purpose of the Study:
- To investigate Streptococcus pneumoniae carriage in healthy Danish children aged 8-19 months.
- To assess the efficacy of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis on pneumococcal carriage.
- To analyze risk factors for carriage and compare findings with invasive pneumococcal disease (IPD) data.
Main Methods:
- A double-blind, randomized controlled trial (ProbiComp study) involving 290 children.
- Children received probiotics or placebo for 6 months during daycare enrollment.
- Pneumococci identification and serotyping using optochin sensitivity, bile solubility, and Quellung reaction.
Main Results:
- The overall carriage rate of S. pneumoniae increased from 26.0% at baseline to 67.4% at the end of the intervention.
- No significant difference in pneumococcal carriage was observed between the probiotic and placebo groups (p=0.508).
- Children carried non-vaccine serotypes prevalent in younger children, but not those common in elderly IPD cases.
Conclusions:
- Probiotics Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis did not significantly alter pneumococcal carriage in this cohort.
- Danish children aged 8-19 months primarily carry S. pneumoniae serotypes not associated with high IPD rates in the elderly.
- Other age groups may be more significant reservoirs for pneumococcal serotypes causing IPD in the elderly, warranting further investigation.
Abstract:
This study examined the carriage of Streptococcus pneumoniae in healthy Danish children aged 8-19 months and assessed the effect of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis on the pneumococcal carriage during daycare enrolment. Potential risk factors of pneumococcal carriage were analysed and the carriage study was compared with registered invasive pneumococcal disease (IPD) data. This study is a part of the ProbiComp study, which was a double-blind, randomized controlled trial, including 290 children allocated to probiotics or placebo for 6 months and recruited during two autumn seasons (2014/2015). Pneumococci were identified by optochin sensitivity, bile solubility, α-hemolysis and/or capsular reaction. Serotyping was performed by latex agglutination kit and Quellung reaction. The carriage rate of S. pneumoniae was 26.0% at baseline and 67.4% at the end of intervention. No significant difference was observed between the placebo group and the probiotics group (p = 0.508). Children aged 8-19 months were carriers of non-pneumococcal vaccine serotypes causing IPD in children aged 0-4 years. However, serotypes causing most IPD cases in Danish elderly were either not found or found with low prevalence suggesting that children are not the main reservoir of those serotypes and other age groups need to be considered as carriers.
Related Concept Videos
Blind Procedures
Blinding
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Clinical Trials: Overview
Trial and Error and Algorithm

